Prognosis
Medtronic Halts Heart Failure Device Sales as Risks Surface
- HVAD device for advanced heart failure has history of recalls
- Rival Abbott says it has capacity for increased device demand
This article is for subscribers only.
Medtronic Plc is halting sales of its HVAD device that helps patients with advanced heart failure pump blood on growing evidence that it leads to more strokes and other adverse events than competing models.
“The company notified physicians to cease new implants of the HVAD system and transition to an alternative means of durable mechanical circulatory support,” Dublin-based Medtronic said Thursday in a statement. The shares fell as much as 1.2% as of 9:53 a.m. in New York.